Neurological disorders associated with COVID-19 in Sri Lanka.
COVID-19
Neurology
SARS-CoV-2
Sri Lanka
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
04 Oct 2023
04 Oct 2023
Historique:
received:
27
03
2023
accepted:
20
09
2023
medline:
1
11
2023
pubmed:
5
10
2023
entrez:
4
10
2023
Statut:
epublish
Résumé
Neurological manifestations of SARS-CoV-2 infection have been reported from many countries around the world, including the South Asian region. This surveillance study aimed to describe the spectrum of neurological disorders associated with COVID-19 in Sri Lanka. COVID-19 patients manifesting neurological disorders one week prior and up to six weeks after infection were recruited from all the neurology centres of the government hospitals in Sri Lanka from May 2021 - May 2022. Data was collected using a structured data form that was electronically transmitted to a central repository. All patients were evaluated and managed by a neurologist. Data were analysed using simple descriptive analysis to characterise demographic and disease related variables, and simple comparisons and logistic regression were performed to analyse outcomes and their associations. One hundred and eighty-four patients with neurological manifestations associated with COVID-19 were recruited from all nine provinces in Sri Lanka. Ischaemic stroke (31%) was the commonest neurological manifestation followed by encephalopathy (13.6%), Guillain-Barre syndrome (GBS) (9.2%) and encephalitis (7.6%). Ischaemic stroke, encephalitis and encephalopathy presented within 6 days of onset of COVID-19 symptoms, whereas GBS and myelitis presented up to 10 days post onset while epilepsy and Bell palsy presented up to 20 - 40 days post onset. Haemorrhagic stroke presented either just prior to or at onset, or 10 - 25 days post onset of COVID-19 symptomatic infection. An increased frequency of children presenting with encephalitis and encephalopathy was observed during the Omicron variant predominant period. A poor outcome (no recovery or death) was associated with supplemental oxygen requirement during admission (Odds Ratio: 12.94; p = 0.046). The spectrum and frequencies of COVID-19 associated neurological disorders in Sri Lanka were similar to that reported from other countries, with strokes and encephalopathy being the commonest. Requiring supplemental oxygen during hospitalisation was associated with a poor outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Neurological manifestations of SARS-CoV-2 infection have been reported from many countries around the world, including the South Asian region. This surveillance study aimed to describe the spectrum of neurological disorders associated with COVID-19 in Sri Lanka.
METHODS
METHODS
COVID-19 patients manifesting neurological disorders one week prior and up to six weeks after infection were recruited from all the neurology centres of the government hospitals in Sri Lanka from May 2021 - May 2022. Data was collected using a structured data form that was electronically transmitted to a central repository. All patients were evaluated and managed by a neurologist. Data were analysed using simple descriptive analysis to characterise demographic and disease related variables, and simple comparisons and logistic regression were performed to analyse outcomes and their associations.
RESULTS
RESULTS
One hundred and eighty-four patients with neurological manifestations associated with COVID-19 were recruited from all nine provinces in Sri Lanka. Ischaemic stroke (31%) was the commonest neurological manifestation followed by encephalopathy (13.6%), Guillain-Barre syndrome (GBS) (9.2%) and encephalitis (7.6%). Ischaemic stroke, encephalitis and encephalopathy presented within 6 days of onset of COVID-19 symptoms, whereas GBS and myelitis presented up to 10 days post onset while epilepsy and Bell palsy presented up to 20 - 40 days post onset. Haemorrhagic stroke presented either just prior to or at onset, or 10 - 25 days post onset of COVID-19 symptomatic infection. An increased frequency of children presenting with encephalitis and encephalopathy was observed during the Omicron variant predominant period. A poor outcome (no recovery or death) was associated with supplemental oxygen requirement during admission (Odds Ratio: 12.94; p = 0.046).
CONCLUSIONS
CONCLUSIONS
The spectrum and frequencies of COVID-19 associated neurological disorders in Sri Lanka were similar to that reported from other countries, with strokes and encephalopathy being the commonest. Requiring supplemental oxygen during hospitalisation was associated with a poor outcome.
Identifiants
pubmed: 37794324
doi: 10.1186/s12883-023-03399-w
pii: 10.1186/s12883-023-03399-w
pmc: PMC10548601
doi:
Substances chimiques
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
351Investigateurs
A Keshavaraj
(A)
U K Ranawaka
(UK)
S Senanayake
(S)
P Ratnayake
(P)
B Senanayake
(B)
M C Caldera
(MC)
D Halahakoon
(D)
D S Wijesekara
(DS)
S Bandusena
(S)
T Chang
(T)
H Gunasekara
(H)
C Gunawardhana
(C)
A Arasalingam
(A)
A Fernando
(A)
D S Liyanage
(DS)
G Pathirana
(G)
T N P Rathnayake
(TNP)
A T Alibhoy
(AT)
D N Weerathunga
(DN)
A Dissanayake
(A)
K Gooneratne
(K)
A Jayawardana
(A)
T Nawasiwatte
(T)
V T Rajendiran
(VT)
D Rathnayake
(D)
J Wanigasinghe
(J)
G J Arhivalaky
(GJ)
S Branavan
(S)
M J N Fernando
(MJN)
K Janarthanan
(K)
K Kariyawasam
(K)
N I Karunasena
(NI)
D Luke
(D)
M K T Madhushanka
(MKT)
S N H Nimesha
(SNH)
M P Priyacharana
(MP)
T D Ruvanpathirana
(TD)
Dput Samarasiri
(D)
S C Weerasinghe
(SC)
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Pediatr Res. 2022 Dec;92(6):1805-1814
pubmed: 35352005
Brain Commun. 2021 Jun 17;3(3):fcab135
pubmed: 34401746
Brain. 2021 Dec 31;144(12):3576-3588
pubmed: 34398188
J Neurol. 2022 Jun;269(6):2827-2839
pubmed: 35353232
JAMA Netw Open. 2021 May 3;4(5):e2112131
pubmed: 33974053
Int J Stroke. 2021 Feb;16(2):137-149
pubmed: 33103610
Brain. 2023 Apr 19;146(4):1648-1661
pubmed: 36087305
Neurology. 2021 Dec 7;97(23):e2269-e2281
pubmed: 34635561
J Neurol. 2022 Mar;269(3):1071-1092
pubmed: 34459986
J Neurol. 2022 Apr;269(4):1731-1740
pubmed: 34652503
J Neural Transm (Vienna). 2021 Nov;128(11):1687-1703
pubmed: 34448930
J Clin Med. 2021 Mar 30;10(7):
pubmed: 33808141
Acta Neurol Scand. 2022 Jul;146(1):6-23
pubmed: 35388457
World J Pediatr. 2022 Jun;18(6):373-382
pubmed: 35476245
Brain Dev. 2022 Nov;44(10):743-747
pubmed: 35835638
J Clin Neurosci. 2021 Nov;93:96-102
pubmed: 34656269
Neurol Sci. 2021 Sep;42(9):3527-3530
pubmed: 34138387
Neurol Clin Pract. 2022 Aug;12(4):e66-e74
pubmed: 36382116
Int J Infect Dis. 2022 Nov;124:45-48
pubmed: 36087642
Lancet Psychiatry. 2020 Oct;7(10):875-882
pubmed: 32593341
Eur J Neurol. 2023 Feb;30(2):413-433
pubmed: 36314485
Epilepsia. 2022 Aug;63(8):e86-e91
pubmed: 35532892
Pediatr Neurol. 2022 Mar;128:33-44
pubmed: 35066369
Brain Commun. 2021 Jul 22;3(3):fcab168
pubmed: 34409289
Front Public Health. 2022 Jun 21;10:873633
pubmed: 35801250
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
BMC Neurol. 2021 Mar 30;21(1):138
pubmed: 33784985